Role of herbal medicines in the management of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials

Ansul Kumar ； Arpita Rai ； Mohd Saif Khan ； Amit Kumar ； Zeya Ul Haque ； Mohammad Fazil ； Gulam Rabbani

《Journal of Traditional and Complementary Medicine》 12卷1期 (2022/01) Pp. 100-113

https://doi.org/10.1016/j.jtcme.2022.01.002

摘要

Background and aim: The management of the worldwide spreading COVID-19 consists of amelioration of its symptoms but no cure is yet available. Herbal medicines supplemented with the Western medicine have been applied for COVID-19 treatment in India, China, Iran, and other countries. This systematic review and meta-analysis of RCTs evaluates the effect and safety of herbal intervention in the management of COVID-19. Experimental procedure: RCTs from databases like PubMed, Cochrane Library, Science Direct, Google Scholar, Science Direct, CTRI, AYUSH Research Portal, India, were reviewed and the data were extracted for study sample demographics, intervention details, clinical effect, inflammatory markers and safety monitoring. Outcomes were expressed as Risk-ratio (RR) with 95% CI for dichotomous data, and Mean- Difference (MD) with 95% CI for continuous data. Result and conclusion: From the 32 eligible studies, a total of 3177 COVID-19 patients were included in the review. Herbal intervention as an adjuvant to Western medicine causes significantly higher improvement compared to Western medicine alone [Fever (RR = 1.09 CI 1.03, 1.15), Cough (Risk- Ratio = 1.22 CI 1.08, 1.37), Fatigue (Risk-Ratio = 1.27 CI 1.11, 1.44), Chest CT Improvement (Risk- Ratio = 1.15 CI 1.08, 1.23)]. The laboratory parameters were also better in the herbal medicine group compared to standard care group only WBC (MD = 0.36 CI 0.16, 0.55), Lymphocyte percentage (MD = 5.48 CI 3.05, 7.92), Absolute lymphocyte count (MD = 0.23 CI 0.07, 0.39), CRP (MD = -5.66 CI -7.96, -3.37). However, duration of hospital stays (MD = -1.82 CI -3.84, 0.21); IL-6 (MD = -3.67 CI -8.76, 1.43), ESR Level (MD = -10.38 CI -25.96, 5.21) were statistically insignificant. No significant adverse events for herbal medications were noted in the included RCTs, during the time of the studies. (n = 665, RR 0.93; 95% CI 0.76, 1.14).

關鍵字

COVID-19 ； Herbal medicine ； Systematic review ； Meta-analysis

參考文獻

Shi Y, Wang G, Cai X, et al. An overview of COVID-19. J Zhejiang Univ - Sci B. 2020;21(5):343-360. https://doi.org/10.1631/jzus.B2000083

Jean S, Lee P, Hsueh P. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436-443. https://doi.org/10.1016/j.jmii.2020.03.034

Liu W, Zhou P, Chen K, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. Can Med Assoc J. 2020;192(27):E734-E744. https://doi.org/10.1503/cmaj.200647

Liu S, Chuang W, Lam W, Jiang Z, Cheng Y. Safety surveillance of traditional Chinese medicine: current and future. Drug Saf. 2015;38(2):117-128. https://doi.org/10.1007/s40264-014-0250-z

Liang S, Fang M, Liang C, et al. Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: a rapid systematic review and meta-analysis of randomized controlled trials. Compl Ther Med. 2021;60, 102744. https://doi.org/10.1016/j.ctim.2021.102744